Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback